Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) will present final clinical data on a transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at the SIO 2026 Annual Scientific Meeting in Savannah, GA (Feb 4-8, 2026).
The ePoster (Abstract #327) will be presented by Clarke Wilkirson, PhD on Feb 6, 2026, 5:30–6:30 PM EST, including a 10-minute talk and 5-minute discussion during the Science and Sips reception.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AMIX declined 0.14%, reflecting a mild negative market reaction. This price movement removed approximately $4K from the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AMIX was down 1.15% while only one momentum peer (MOVE) screened, falling about 4.97%. Other listed peers had mixed, mostly modest moves, indicating this news appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Clinical data update | Positive | +2.8% | ASCO GI subgroup data showing rapid, durable pain relief across disease stages. |
| Dec 30 | Patent grant | Positive | +8.3% | European patent granted on cardiac neuromodulation platform technology. |
| Dec 23 | Investor presentation | Positive | -7.0% | CEO outlined IP strengthening and multi-indication expansion strategy. |
| Dec 18 | Conference abstract | Positive | +4.6% | ASCO GI 2026 poster acceptance on long-term pancreatic pain mitigation data. |
| Nov 26 | CEO commentary | Positive | +10.2% | CEO Corner discussing IP protection and expansion beyond pancreatic cancer. |
Recent company-specific announcements, especially clinical and IP milestones, have more often been followed by positive price reactions, with only one notable divergence on a strategy-focused CEO event.
Over the last few months, AMIX has highlighted clinical progress and platform expansion. A Jan 9, 2026 ASCO GI update (news_id 955378) on pancreatic cancer pain relief saw a positive move. Late Dec 2025 brought a European patent grant (news_id 951842) and IP/platform strategy commentary (news_id 951084). Earlier, an ASCO GI poster selection (news_id 949618) and a CEO Corner segment on strategic growth (news_id 941246) also supported an innovation-focused narrative that this SIO presentation announcement fits into.
Regulatory & Risk Context
An effective S-3 shelf dated Nov 26, 2025 registers 13,504,998 warrant shares for resale; AMIX would receive up to $7.7 million only if the Common Warrants are exercised in cash, and full exercise would significantly increase the share count.
Market Pulse Summary
This announcement adds another visibility milestone for AMIX’s transvascular RF ablation approach in pancreatic cancer by taking final pain-mitigation data to the SIO 2026 meeting. It follows recent ASCO GI presentations and IP-focused updates, reinforcing a strategy centered on clinical validation and platform exposure. At the same time, regulatory filings highlight ongoing net losses of $7.5 million in the last quarter, limited cash of $7.5 million, and reliance on facilities such as a $15.0 million equity purchase agreement and warrant structures for funding.
Key Terms
transvascular radiofrequency (RF) ablation medical
pancreatic adenocarcinoma medical
neurolysis medical
interventional oncology medical
AI-generated analysis. Not financial advice.
THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that final clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting happening February 4-8, 2026 in Savannah, GA.
The presentation, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Final Analysis of Neurolysis via Transvascular Radiofrequency (RF) Ablation,” has been accepted as an ePoster presentation for the conference’s Science and Sips Reception, highlighting emerging innovations in interventional oncology.
The ePoster (Abstract #327) will be presented by Clarke Wilkirson, PhD on Friday, February 6, 2026, from 5:30 PM to 6:30 PM EST, in the ePoster corridor outside the exhibit hall. As part of the Science and Sips program, the presentation will include a dedicated 15-minute session consisting of a 10-minute presentation followed by a 5-minute discussion period.
“Pain remains one of the most debilitating and difficult-to-treat complications for patients with pancreatic cancer,” said Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix. “We are pleased to present the final analysis of this study at the SIO 2026 Annual Scientific Meeting, as it highlights the potential of our transvascular RF ablation approach to address a significant unmet clinical need. We believe this minimally invasive therapy may offer a meaningful opportunity to improve pain control and quality of life for patients facing this devastating disease.”
The SIO Annual Scientific Meeting brings together leading clinicians, researchers and innovators focused on advancing minimally invasive, image-guided therapies for cancer care. For more details, please visit the conference website here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
When will Autonomix (AMIX) present the final analysis on RF ablation at SIO 2026?
What is the focus of Autonomix's (AMIX) ePoster Abstract #327 at SIO 2026?
Who will present Autonomix's (AMIX) final clinical data at the SIO 2026 meeting?
Where and in what format will Autonomix (AMIX) present its SIO 2026 findings?
How does Autonomix (AMIX) describe the clinical relevance of the transvascular RF approach?
